Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05557162 · ClinicalTrials.gov registry record · NA
Artificial Intelligence Enhanced ECG to Detect Cardiac Amyloidosis
A NA study, sponsored by Mayo Clinic.
- Completed
- Registry status
- NA
- Development phase
- 20,143
- Enrollment target
NCT05557162: Completed NA study, sponsored by Mayo Clinic.
NCT05557162 is a NA study that has completed, run by Mayo Clinic. The registered enrollment target is 20,143 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05557162, a NA study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- NA
- Development phase
- 20,143 participants
- Enrollment target
Study Summary
The purpose of this study is to assess a novel artificial intelligence (AI)-enabled electrocardiogram (ECG)-based screening tool for improving the diagnosis of cardiac amyloidosis (CA).
Interventions
- OTHER AI ECG Amyloid algorithm
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20,143 participants |
| Start Date | 2023-06-19 |
| Est. Completion | 2025-07-23 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05557162
The ClinicalTrials.gov registry entry for NCT05557162 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 20,143 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which AI ECG Amyloid algorithm is the first listed.
NCT05557162 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05557162 about?
NCT05557162 is a clinical study titled "Artificial Intelligence Enhanced ECG to Detect Cardiac Amyloidosis". The purpose of this study is to assess a novel artificial intelligence (AI)-enabled electrocardiogram (ECG)-based screening tool for improving the diagnosis of cardiac amyloidosis (CA).
What is the current status of trial NCT05557162?
This trial is currently completed. It is a NA study. The enrollment target is 20,143 participants. The study started on 2023-06-19. Estimated completion is 2025-07-23.
What interventions are being tested in trial NCT05557162?
The interventions under investigation include: AI ECG Amyloid algorithm (OTHER).
Who is sponsoring clinical trial NCT05557162?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.